

CALYXHA endeavors to develop novel approaches to tissue degenerative diseases and receives support from Austrian VC and international investors

Vienna, 4th of March, 2020

Austrian biotech company CALYXHA Biotechnologies GmbH announces the investment received from ARAX Capital Partners that complements the previously secured seed funding from investors, including seasoned life science financiers KINLED Holding, Olipan Investments, the Blom Family Office, and LifeLink Ventures. This seed financing supports the pre-clinical development of CALYXHA's lead product candidate, CAL-X.

CALYXHA is pursuing a new approach to develop therapeutics to diseases that involve tissue degenerative processes. Drug candidates have been discovered by an in-silico drug discovery platform developed by CALYXHA co-founder Prof. Robert Konrat and his group (University of Vienna). The mechanism of action for these candidates is radically novel and targets several of the pathological processes of tissue degeneration involved in many diseases, especially in those that are more frequent as the consequence of ageing.

“We are delighted to receive this funding from ARAX that will accelerate the pre-clinical development of our lead candidate and broadens the scope of proof-of-concept studies in disease areas where we expect efficacy from our radically new disease modifying approach. Selection of the lead indication for clinical development will be based on efficacy data and clinical feasibility”. – commented Eszter Nagy MD, PhD, Co-founder and CEO of CALYXHA.

CALYXHA is focusing on disease areas associated with high medical need, huge market potential and intensive drug development activity in the pharmaceutical industry, such as neurodegenerative diseases, chronic inflammation, and tissue degenerative diseases associated with ageing.

“We are excited to join the existing consortium of experienced private investors and enable CALYXHA to accelerate its pre-clinical activities. Due to the unique mechanism, we see a great potential for the CALYXHA approach in multiple disease areas that will allow the company to generate revenue through pharma partnerships while pursuing its product development in other areas” – said Patrik Cesky from ARAX Capital Partners.

ABOUT CALYXHA

CALYXHA Biotechnologies GmbH (<http://www.calyxha.com/>) is a product development company in the pre-clinical stage and also applies its drug discovery technology in industry partnerships. CALYXHA was founded in 2019 by Eszter Nagy MD PhD, Founder and CEO of CEBINA GmbH (Central European Biotech Incubator and Accelerator), Co-founder and President of Eveliqre Biotechnologies GmbH, previously Co-founder and CSO of Arsanis Inc, Vice President and Global Head of Research at Intercell AG (now Valneva SAS); Prof Robert Konrat, PhD (University of Vienna, Max F. Perutz Laboratories) and scientists Marco Sealey, PhD and Tanja Gesell, PhD; Wolfgang Friedl and CEBINA GmbH. CALYXHA is incubated and accelerated by CEBINA GmbH (www.cebina.eu).

ABOUT ARAX CAPITAL PARTNERS

Arax Capital Partners is an Austrian venture capital company. The investment focus concentrates on innovative and growth-oriented high-tech and bio-tech companies which require growth capital to realize their business ideas. The company is privately owned. (www.arax.at)

* * *

CONTACT

Eszter Nagy, CEO
+ 43 1 909220-82310
eszter.nagy@calyxha.com

Media enquiries to:
Sophie Zettl, PhD
+ 43 1 909220-82313
sophie.zettl@cebina.eu